Innovation

Driven by Compassion

Home

Supporting people living with hidradenitis suppurativa (HS)

During HS Awareness Week (June 1-7, 2025) and every other week, we're dedicated to helping people who live with this serious disease. Learn about the LOTUS HS trial >

About Us

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases.

Our Pipeline

Avalo’s lead asset is AVTX-009,
an anti-IL-1β mAb, targeting inflammatory diseases.

Presentations


June 2025 Corporate Presentation

 

Recent News

May 27, 2025 10:05 am
Avalo Therapeutics to Participate in Upcoming Investor Conferences
May 12, 2025 7:00 am
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
View All News
June 2025 Corporate Presentation View 10-K View Investor Relations